Clinical Trials
2 trialsNCT02675946 2022-01-26
CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)
Curegenix Inc.
Phase 1 Unknown
NCT03507998 2020-07-24
Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors
Curegenix Inc.
Phase 1 Unknown